文献速递糖尿病

高浓度eNAMPT的结构功能变化介导2型糖尿病β细胞功能障碍

Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes.
PubMed 文献 · Diabetologia · 2019-11-15

研究探讨eNAMPT对胰岛β细胞功能量的结构功能依赖性效应,发现低浓度(约1 ng/ml)二聚体eNAMPT通过NAD依赖机制增强β细胞功能,而高浓度(约5 ng/ml)单体eNAMPT通过NAD非依赖促炎机制导致β细胞功能障碍、身份丧失、凋亡增加及α细胞增多,与2型糖尿病β细胞衰竭相关。

要点

  • 低浓度eNAMPT以二聚体形式通过NAD依赖机制维持β细胞功能与身份。
  • 高浓度eNAMPT转为单体形式,经NAD非依赖促炎机制诱导β细胞功能障碍和凋亡。
  • 选择性靶向单体eNAMPT可能成为2型糖尿病治疗新策略。

核心结论

  • eNAMPT对β细胞功能量呈浓度和结构功能依赖的双相效应,高浓度单体eNAMPT通过NAD非依赖促炎机制诱导糖尿病样胰岛表型。

研究设计与样本

  • 使用CD-1小鼠及来自BodyFatS&H研究的非糖尿病、空腹血糖受损(IFG)或2型糖尿病肥胖人类血清,以及VaSera试验中患有或面临2型糖尿病风险者的血清。
  • 生成重组野生型和单体eNAMPT,在分离的小鼠和人类胰岛中探究其对功能β细胞量的影响。

主要发现

  • 低生理浓度(约1 ng/ml,如非糖尿病人类血清)eNAMPT通过NAD依赖机制增强β细胞功能,与二聚体形式一致。
  • 当eNAMPT浓度升至约5 ng/ml(如2型糖尿病)时,eNAMPT开始采用单体形式,通过NAD非依赖促炎机制介导β细胞功能障碍、β细胞身份和数量减少、α细胞数量增加及凋亡增加。

关键数值与推荐

  • 低生理浓度约1 ng/ml eNAMPT以二聚体形式通过NAD依赖机制增强β细胞功能。
  • 高浓度约5 ng/ml eNAMPT以单体形式通过NAD非依赖促炎机制诱导β细胞功能障碍。

临床怎么用

  • 选择性靶向单体eNAMPT可能成为2型糖尿病的有前景治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Progressive decline in functional beta cell mass is central to the development of type 2 diabetes. Elevated serum levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) are associated with beta cell failure in type 2 diabetes and eNAMPT immuno-neutralisation improves glucose tolerance in mouse models of diabetes. Despite this, the effects of eNAMPT on functional beta cell mass are poorly elucidated, with some studies having separately reported beta cell-protective effects of eNAMPT. eNAMPT exists in structurally and functionally distinct monomeric and dimeric forms. Dimerisation is essential for the NAD-biosynthetic capacity of NAMPT. Monomeric eNAMPT does not possess NAD-biosynthetic capacity and may exert distinct NAD-independent effects. This study aimed to fully characterise the structure-functional effects of eNAMPT on pancreatic beta cell functional mass and to relate these to beta cell failure in type 2 diabetes. METHODS: CD-1 mice and serum from obese humans who were without diabetes, with impaired fasting glucose (IFG) or with type 2 diabetes (from the Body Fat, Surgery and Hormone [BodyFatS&H] study) or with or at risk of developing type 2 diabetes (from the VaSera trial) were used in this study. We generated recombinant wild-type and monomeric eNAMPT to explore the effects of eNAMPT on functional beta cell mass in isolated mouse and human islets. Beta cell function was determined by static and dynamic insulin secretion and intracellular calcium microfluorimetry. NAD-biosynthetic capacity of eNAMPT was assessed by colorimetric and fluorescent assays and by native mass spectrometry. Islet cell number was determined by immunohistochemical staining for insulin, glucagon and somatostatin, with islet apoptosis determined by caspase 3/7 activity. Markers of inflammation and beta cell identity were determined by quantitative reverse transcription PCR. Total, monomeric and dimeric eNAMPT and nicotinamide mononucleotide (NMN) were evaluated by ELISA, western blot and fluorometric assay using serum from non-diabetic, glucose intolerant and type 2 diabetic individuals. RESULTS: eNAMPT exerts bimodal and concentration- and structure-functional-dependent effects on beta cell functional mass. At low physiological concentrations (~1 ng/ml), as seen in serum from humans without diabetes, eNAMPT enhances beta cell function through NAD-dependent mechanisms, consistent with eNAMPT being present as a dimer. However, as eNAMPT concentrations rise to ~5 ng/ml, as in type 2 diabetes, eNAMPT begins to adopt a monomeric form and mediates beta cell dysfunction, reduced beta cell identity and number, increased alpha cell number and increased apoptosis, through NAD-independent proinflammatory mechanisms. CONCLUSIONS/INTERPRETATION: We have characterised a novel mechanism of beta cell dysfunction in type 2 diabetes. At low physiological levels, eNAMPT exists in dimer form and maintains beta cell function and identity through NAD-dependent mechanisms. However, as eNAMPT levels rise, as in type 2 diabetes, structure-functional changes occur resulting in marked elevation of monomeric eNAMPT, which induces a diabetic phenotype in pancreatic islets. Strategies to selectively target monomeric eNAMPT could represent promising therapeutic strategies for the treatment of type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sayers SR, Beavil RL, Fine NHF, et al. Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes. Diabetologia. 2019. PMID: 31732790. doi:10.1007/s00125-019-05029-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。